baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Hepion Pharmaceuticals/ US4268973025 /

2024-04-18 3:31:06 PM	Chg. +0.02	Volume	Bid-	Ask-	High	Low
2.10USD	+0.96%	100 Turnover: 210	-Bid Size: -	-Ask Size: -	2.10	2.10

GlobeNewswire 03-06 Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

GlobeNewswire 02-16 Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross...

GlobeNewswire 01-03 Hepion Pharmaceuticals to Present at NASH-TAG 2024

GlobeNewswire 2023-12-07 Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Chan...

GlobeNewswire 2023-11-28 Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit

GlobeNewswire 2023-11-13 Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in ...

GlobeNewswire 2023-11-10 Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘AL...

GlobeNewswire 2023-10-25 Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Can...

GlobeNewswire 2023-09-29 Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Plac...

GlobeNewswire 2023-09-21 Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference

GlobeNewswire 2023-09-21 New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening ...

GlobeNewswire 2023-09-19 Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer

GlobeNewswire 2023-09-06 Hepion Pharmaceuticals Announces Management Changes

GlobeNewswire 2022-03-07 Hepion Pharmaceuticals to Present at the Q1 Investor Summit Conference

GlobeNewswire 2022-02-15 Hepion Pharmaceuticals Appoints World-Renowned Hepatologist, Dr. Eddie C. Cheung, to Lead the Compan...

GlobeNewswire 2022-02-14 Hepion Pharmaceuticals to Present at BIO CEO & Investor Conference

GlobeNewswire 2022-01-12 Hepion Pharmaceuticals Announces Death of Director, Thomas Adams

GlobeNewswire 2022-01-06 Hepion Pharmaceuticals Announces USAN Selection of “Rencofilstat” as Nonproprietary Name for CRV431

GlobeNewswire 2022-01-05 Hepion Pharmaceuticals Announces Participation in the H.C. Wainwright BioConnect Conference

GlobeNewswire 2022-01-05 Hepion Pharmaceuticals to Present Clinical Data at NASH-TAG Conference

GlobeNewswire 2021-12-21 Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liv...

GlobeNewswire 2021-11-16 Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver ...

GlobeNewswire 2021-11-10 Anti-Cancer Mechanism of Hepion Pharmaceuticals’ CRV431 Highlighted in Scripps Research Institute Po...

GlobeNewswire 2021-11-02 Hepion Pharmaceuticals to Present at the EquitiesIQ Q4 2021 Investor Forum

GlobeNewswire 2021-10-07 Hepion Pharmaceuticals to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference

Hepion Pharmaceuticals/ US4268973025 /

If you wish to receive reply to your feedback, please provide your email address.